Tukysa 150 mg Alternative – Tucaxen (Tucatinib) 150 mg Tablet | Everest Pharmaceuticals
Tucaxen 150 mg (Tucatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tukysa (Seagen / Pfizer). It belongs to the HER2 tyrosine kinase inhibitor class and is used in selected HER2-positive breast cancer treatment combinations.
Active ingredient: Tucatinib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Tucaxen 150 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Tucatinib. It is listed here as a same-ingredient branded option for people researching Tukysa, a reference brand associated with Seagen / Pfizer. Tucaxen and Tukysa must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 150 mg strength.
Tucaxen vs. Tukysa – Originator / Reference Brand Comparison
Tukysa is a widely recognized reference brand for Tucatinib associated with Seagen / Pfizer. Tucaxen is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Tucaxen is manufactured by Seagen / Pfizer, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Tucatinib
Strength: 150 mg
Dosage form: Tablet
Pharmacological class: HER2 tyrosine kinase inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Tucatinib is used in selected HER2-positive breast cancer treatment combinations. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Tucatinib Works
Tucatinib is a HER2 tyrosine kinase inhibitor. In general, it blocks HER2 kinase signaling involved in cancer-cell growth. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 150 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Tucatinib include: diarrhea, liver injury and interactions. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Tucatinib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include diarrhea, liver injury and interactions. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Tucatinib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Tucatinib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Tucaxen Listed as an Alternative to Tukysa?
This listing helps customers identify an Everest Pharmaceuticals product containing Tucatinib while researching Tukysa. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Tucaxen
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Tukysa
Reference company: Seagen / Pfizer
Generic ingredient: Tucatinib
Strength: 150 mg
Dosage form: Tablet
Therapeutic class: HER2 tyrosine kinase inhibitor
Frequently Asked Questions
What is Tucaxen 150 mg?
It is an Everest Pharmaceuticals tablet containing Tucatinib 150 mg.
Is Tucaxen the same as Tukysa?
They are presented as brands associated with Tucatinib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Tucatinib used for?
Tucatinib is used in selected HER2-positive breast cancer treatment combinations, subject to the applicable label and clinical assessment.
How does Tucatinib work?
It blocks HER2 kinase signaling involved in cancer-cell growth.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Tucatinib |
|---|---|
| Strength | 150 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 30 tablets |
Related products
Alecensa 150 mg Alternative – Alecnib (Alectinib) 150 mg Capsule | Everest Pharmaceuticals
Alecnib 150 mg (Alectinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Alecensa (Roche / Genentech). It belongs to the ALK inhibitor class and is used in appropriately tested ALK-positive non-small cell lung cancer.
Active ingredient: Alectinib
Strength: 150 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Arimidex 1 mg Alternative – Anastrol (Anastrozole) 1 mg Tablet | Beacon Pharmaceuticals
Ibrance 125 mg Alternative – Palbocent (Palbociclib) 125 mg Capsule | Incepta Pharmaceuticals
Palbocent 125 mg (Palbociclib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Ibrance (Pfizer).
Pack: 21 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Nolvadex 20 mg Alternative – Tamoxi (Tamoxifen) 20 mg Tablet | Beacon Pharmaceuticals
Tykerb 250 mg Alternative – Certus (Lapatinib) 250 mg Tablet | Beacon Pharmaceuticals
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xeloda 500 mg Alternative – Capixet (Capecitabine) 500 mg Tablet | Everest Pharmaceuticals
Capixet 500 mg (Capecitabine) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xeloda (Roche). It belongs to the oral fluoropyrimidine chemotherapy class and is used in selected colorectal, breast and other cancer regimens.
Active ingredient: Capecitabine
Strength: 500 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.